Management of asymptomatic myeloma patients

References

• Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980;302(24):1347-9
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749-57
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23(1):3-9
   PubMed Web of Science ®Google Scholar
• Blade J, Dimopoulos M, Rosinol L, et al. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010;28(4):690-7
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk smoldering myeloma. N Engl J Med 2013;369(18):1762-3
   PubMed Web of Science ®Google Scholar
• Lopez-Corral L, Corchete LA, Sarasquete ME, et al. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica 2014;99(8):1365-72
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117(18):4701-5
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356(25):2582-90
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011;365(5):474-5
   PubMed Web of Science ®Google Scholar
• Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2012;27(4):947-53
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Mick R, Garfall AL, et al. Modeling the risk of progression in smoldering multiple myeloma. J Clin Oncol 2014;32(5s Suppl):abstract 8607
   Google Scholar
• Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110(7):2586-92
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Mateo G, Garcia-Sanz R, et al. Risk of progression in smoldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010;148(1):110-14
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111(2):785-9
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27(4):941-6
   PubMed Web of Science ®Google Scholar
• Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013;27(3):680-5
   PubMed Web of Science ®Google Scholar
• Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003;123(4):631-6
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014;123(1):78-85
   PubMed Web of Science ®Google Scholar
• Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28(9):1606-10
   PubMed Web of Science ®Google Scholar
• Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014;28(9):1902-8
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013;31(34):4325-32
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013;27(8):1738-44
   PubMed Web of Science ®Google Scholar
• Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993;50(2):95-102
   PubMed Web of Science ®Google Scholar
• Grignani G, Gobbi PG, Formisano R, et al. A prognostic index for multiple myeloma. Br J Cancer 1996;73(9):1101-7
   PubMed Web of Science ®Google Scholar
• Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 2000;82(7):1254-60
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17(4):775-9
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21(1):16-19
   PubMed Web of Science ®Google Scholar
• Barlogie B, van Rhee F, Shaughnessy JDJr, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112(8):3122-5
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009;84(2):114-22
   PubMed Web of Science ®Google Scholar
• Korde N, Carlsten M, Lee MJ, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 2014;99(6):e81-3
   PubMed Web of Science ®Google Scholar
• Witzig TE, Laumann KM, Lacy MQ, et al. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia 2013;27(1):220-5
   PubMed Web of Science ®Google Scholar
• Martin A, Garcia-Sanz R, Hernandez J, et al. Pamidronate induces bone formation in patients with smoldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol 2002;118(1):239-42
   PubMed Web of Science ®Google Scholar
• D’Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma 2011;52(5):771-5
   PubMed Web of Science ®Google Scholar
• Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113(7):1588-95
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369(5):438-47
   PubMed Web of Science ®Google Scholar
• Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013;54(10):2215-18
   PubMed Web of Science ®Google Scholar
• Landgren O, Mailankody S, Kwok M, et al. Clinical and correlative pilot study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRd – R) in high risk smoldering multiple myeloma patients. Blood 2013;122(21):1939
   Web of Science ®Google Scholar